Effects of sustained-release oral phenylpropanolamine on the nasal mucosa of healthy subjects.
Phenylpropanolamine (PPA) is widely used as a nasal decongestant administered orally in sustained release preparations and, in Sweden, the recommended dose nowadays is 50 mg twice daily for adults. The aim of this placebo-controlled, cross-over study was to determine the onset and duration of the de...
| Published in: | Acta Oto-Laryngologica Vol. 119; no. 7; pp. 837 - 843 |
|---|---|
| Main Authors: | , , , |
| Format: | clinical trial research Journal Article |
| Published: |
Taylor & Francis Ltd
12/30/99
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106093804&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 106093804 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00016489 B6D jtl: Acta Oto-Laryngologica issn: 00016489 maglogo: Y pubinfo: dt: 12/30/99 vid: 119 iid: 7 pid: 377 pub: Taylor & Francis Ltd place: Philadelphia, Pennsylvania artinfo: ui: 106093804 2009436427 10.1080/00016489950180513 NLM10687944 106093804 ppf: 837 ppct: 6 formats: fmt: @attributes: type: P tig: atl: Effects of sustained-release oral phenylpropanolamine on the nasal mucosa of healthy subjects. aug: au: Graf P Toll K Palm J Hallén H sug: subj: Phenylpropanolamine Administration and Dosage Vasoconstrictor Agents, Nasal Administration and Dosage Administration, Intranasal Administration, Oral Adult Aerosols Blood Pressure Drug Effects Clinical Trials Crossover Design Delayed-Action Preparations Dose-Response Relationship, Drug Female Hypertension Chemically Induced Male Oxymetazoline Administration and Dosage Oxymetazoline Adverse Effects Phenylpropanolamine Adverse Effects Vasoconstrictor Agents, Nasal Adverse Effects Human Adult: 19-44 years Female Male ab: Phenylpropanolamine (PPA) is widely used as a nasal decongestant administered orally in sustained release preparations and, in Sweden, the recommended dose nowadays is 50 mg twice daily for adults. The aim of this placebo-controlled, cross-over study was to determine the onset and duration of the decongestive effect of 50 and 100 mg PPA in 15 healthy subjects. All subjects arrived at the laboratory at 07.30 h. After an acclimatisation, the nasal mucosal baseline was established with rhinostereometry and the minimal cross-sectional area was measured using acoustic rhinometry. The systolic and diastolic blood pressures were also determined. Then all subjects were given their study drugs for the day and the measurements were repeated every hour for 8 h. This procedure was repeated for 3 days at 48 h intervals between the days. For purposes of comparison, the decongestive effect of oxymetazoline nasal spray was studied on a separate day. The decongestive effect of 100 mg PPA was similar to that of topical oxymetazoline. It develops after 1 h and lasts for approximately 6 h. The decongestive effect of oxymetazoline was significantly greater than that of 50 mg PPA and that of 100 mg PPA was significantly greater than that of 50 mg PPA using rhinostereometry, but not when using acoustic rhinometry. However, 50 mg PPA had no significant decongestive effect, compared with placebo, with rhinostereometry or acoustic rhinometry. In the first 3 h after administration of PPA, there was a dose-response increase in the systolic and diastolic blood pressures, which then returned to baseline. In conclusion, this study shows that PPA in double the recommended dose, i.e. 100 mg, has a significant decongestive effect on the nasal mucosa in healthy subjects. However, when the dose of PPA is increased the systolic and diastolic blood pressures also increase. pubtype: Academic Journal doctype: clinical trial research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|